Oncolytics Biotech Inc. (ONC.TO)
| Previous Close | 1.4900 |
| Open | 1.5000 |
| Bid | 1.4400 x 0 |
| Ask | 1.4500 x 0 |
| Day's Range | 1.4400 - 1.5000 |
| 52 Week Range | 1.2000 - 4.4900 |
| Volume | |
| Avg. Volume | 69,780 |
| Market Cap | 109.359M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4000 |
| Earnings Date | Aug 12, 2024 - Aug 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.66 |
- Baystreet
Stocks in play: Oncolytics Biotech Inc
Today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Wednesday, ...
CNW GroupOncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Wednesday, May 15, 2024. A total of 41.34% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.
CNW GroupOncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it has entered into a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR). The purpose of the preliminary collaboration is to commence planning activities for the evaluation of pelareorep in the treatment of first-line metastatic pancreatic ductal adenocarcinoma (PDAC) as part of GCAR's anticipated master protocol for m
